The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2030 Strategy, setting out ambitious plans to translate scientific and technological innovation into better health outcomes. The regulator says that the commitments will enable it to keep pace with rapid advances in science, technology and personalised… Read More
The Association of the British Pharmaceutical Industry (ABPI) has launched its first Youth Advisory Council, a new advisory body made up of young people aged 16 to 19 from across the UK, tasked with challenging and shaping how the pharmaceutical industry inspires, engages and communicates with the next generation. Read More
Ahead of the Budget, UK life sciences groups have called on the Chancellor to prioritise investment in new medicines. The UK government has set out bold targets for the UK’s life sciences sector. By 2030, it wants the UK to lead Europe in commercial research and development… Read More
The Association of the British Pharmaceutical Industry’s (ABPI’s) 2026 flagship Competitiveness Report finds the UK has begun to reverse years of decline. However, the Association cautions that sustained delivery of government commitments will now determine whether the recovery holds. Since September 2025, the global pharmaceutical… Read More
The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme. In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme… Read More
The recent decision by the National Institute of Health and Care Excellence (NICE) to reject two Alzheimer’s drugs on the basis of “not providing good value for money” was met with considerable disappointment. Pharmaceutical company Eisai, developer of the rejected therapy lecanemab, was understandably disappointed , saying it was… Read More
The UK government has doubled the rate that pharmaceutical companies repay on the sales of newer products to the NHS under the statutory scheme for branded medicines to a record 31%. Following a consultation, the government has decided to raise the statutory scheme payment rate for newer… Read More
The UK could lose out on £11 ($14.8) billion in pharmaceuticals research and development (R&D) investment by 2033, according to WPI Economics. In the UK, the Voluntary Scheme or VPAG requires companies to pay the Department of Health and Social Care (DHSC) up to a quarter to… Read More
The Association of the British Pharmaceutical Industry (ABPI) has announced that Russel Abberley, the Vice President and General Manager of Amgen UK and Ireland, will become the organisation’s new president, after having held the role on an interim basis. Abberley will take up the role on 13… Read More
Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the Code of Practice has come to an end. The company’s return to full membership of the ABPI follows extensive audits of Novo Nordisk’s compliance procedures and… Read More
The Association of the British Pharmaceutical Industry (ABPI) has warned that “rocketing payment rates are undermining the UK government’s efforts to make life sciences a key pillar of its industrial strategy”. The government is proposing to raise the Statutory Scheme payment rate for newer branded medicines from… Read More
Health and care researchers at The King’s Fund are calling for the UK government and national NHS leaders to play a greater role in developing guidance and providing leadership of health service partnerships with the life sciences industry. The UK has a large and thriving life… Read More
With a new UK Budget looming on 30 October, the first of this new Labour government, the Chancellor has been urged to protect the country’s life sciences sector and increase investment in medicines. Concerns have been raised in response to rumours of potential cuts to UK… Read More
Younger workers in the UK are increasingly choosing careers in pharmaceuticals over other industries like technology or finance due to perceptions of better work life balance and social purpose in the sector. This is according to a new report ‘Young people’s perceptions of careers in the… Read More
The Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Novartis, Pfizer, Otsuka and Novo Nordisk have breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. The companies were judged to have “brought discredit upon”, and “reduced confidence in”, the pharmaceutical industry. Read More
By DDW Editor Reece Armstrong The upcoming general election in the UK has placed the priorities of the country into the spotlight and the drug discovery sector should in no way be forgotten. Economic uncertainty, challenging global conditions and a healthcare system facing serious pressures, means that whatever government takes the… Read More
